This reference page presents Price Action Indicator forecast data for Bicara Therapeutics Common. The projected values and error metrics are presented below as reference information.
Price Action Indicator (or PAIN) was developed by Michael B. Geraty and published in 'Futures' magazine in August 1997. This Price Action Indicator forecast data for Bicara Therapeutics Common is sourced from the most recent available trading data and is intended solely as reference information.
Price Action Indicator Analysis Today
Bicara Therapeutics Common has current Price Action Indicator of -0.11. Price Action indicator evaluates an asset for a given trading period using the following formula: ((close - open) + (close - high) + (close - low)) / 2. This indicator is consistent with the interpretation of Japanese candlestick patterns.
On March 23 2026 Bicara Therapeutics Common was traded for 18.39 at the closing time. The top price for the day was 18.93 and the lowest listed price was 18.06 . The trading volume for the day was 324.3 K. The trading history from March 23, 2026 did not affect price variability. The overall trading delta against the current closing price is 1.14% .
Price Action Indicator (or PAIN) was developed by Michael B. Geraty and published in 'Futures' magazine in August 1997.
Bicara Therapeutics' daily price returns can be decomposed into trend, seasonal, and residual components. Divergence between short-term and long-term averages in Bicara often signals an upcoming reversal or acceleration.
The peer firms below within the Health Care space can help frame Bicara Therapeutics' pricing and running costs in context. Key comparison metrics include price-to-earnings, profit margin, and revenue growth across Bicara Therapeutics' peer group.
Market strength indicators help investors evaluate how Bicara Therapeutics stock reacts to evolving market conditions. These indicators help determine optimal entry and exit points for trading Bicara Therapeutics Common.
The analysis of Bicara Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. Understanding the risk involved in holding Bicara Therapeutics' allows investors to make informed decisions about their exposure.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Bicara Therapeutics
A coverage review of Bicara Therapeutics Common shows when the security is attracting above-average attention from contributors and market observers. Used properly, this context can help investors judge whether visibility is reinforcing the thesis or attracting more speculative pressure.
Short sentiment tied to Bicara Therapeutics Common matters because heavier bearish pressure can change how quickly future price expectations become unstable. A disciplined short-interest review can make timing decisions more informed under rising skepticism.
Common Stock Shares Outstanding
54.4 M
Cash And Short Term Investments
489.7 M
More Resources for Bicara Stock Analysis
A clear view of Bicara Therapeutics comes from reviewing its financial structure and trends. These indicators describe how financial results are generated.
